Partnering For Progress: Enhancing Patient Adherence Through Autoinjector Access

By Enrico Zanetti, Executive Director of Commercial Development, Drug Product and Finished Goods, Cristina Brinkmann, Drug Product and Finished Goods Business Steering Group Lead, and Francisco Gonzalez, Associate Director of Strategic Technical Marketing

Autoinjector-Insulin-Pen-Delivery-Device-GettyImages- 1086688132

The COVID-19 pandemic spurred a healthcare revolution that centers around more accessible treatment options for chronic illnesses. This has fueled the demand for convenient drug delivery methods, particularly autoinjectors. Autoinjectors are user-friendly drug delivery devices that allow patients to self-administer precise medication doses. These devices, powered by a spring mechanism, improve medication adherence and patient experience. As a result, the autoinjector market is booming, expected to reach $1.7 billion by 2028 and grow at a 14% compound annual growth rate from 2023 to 2028.

To capitalize on this trend, drug developers should consider partnering with experienced device manufacturers that can recommend the optimal autoinjector format based on volume and viscosity as well as drug product and finished goods providers that can conduct efficient filling and finishing of autoinjectors for patient use. Strategic partnerships such as these help ensure that your treatment reaches patients in a convenient, accessible autoinjector format, allowing for hassle-free treatment at home.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online

FUJIFILM Diosynth Biotechnologies